135 related articles for article (PubMed ID: 11649896)
1. How many subjects are required for a study?
McLarty JW; Levine RJ
IRB; 1987; 9(5):1-3. PubMed ID: 11649896
[No Abstract] [Full Text] [Related]
2. Rate of refusal to participate in clinical trials.
Shimm DS; Spece RG
IRB; 1992; 14(2):7-9. PubMed ID: 11651246
[No Abstract] [Full Text] [Related]
3. The ethical approach to randomization in oncology.
Arpaillange P; Dion S
Drugs Exp Clin Res; 1986; 12(1-2-3):99-103. PubMed ID: 11650154
[No Abstract] [Full Text] [Related]
4. Perspectives of protocol reviewers.
Moline ML; Aisen MW
J Calif Alliance Ment Ill; 1994; 5(1):59-60. PubMed ID: 11653327
[No Abstract] [Full Text] [Related]
5. Ethics of drug experimentation.
Sgreccia E
Dolentium Hominum; 1987; 4(2nd Yr. 1):60-75. PubMed ID: 11653200
[No Abstract] [Full Text] [Related]
6. Guidelines Relevant to the Procedure for Conduct of Clinical Trials.
Ireland. National Drugs Advisory Board
Int Dig Health Legis; 1987; 38(2):376-83. PubMed ID: 11649270
[No Abstract] [Full Text] [Related]
7. The case for per patient payments.
Lewis JP
IRB; 1988; 10(5):9. PubMed ID: 11650075
[No Abstract] [Full Text] [Related]
8. Why I oppose drug company payment of physician/investigators on a per patient/subject basis.
Roizen R
IRB; 1988; 10(1):9-10. PubMed ID: 11658990
[No Abstract] [Full Text] [Related]
9. Pharmacological and psychological research on AIDS: some ethical considerations.
Perry SW
IRB; 1987; 9(5):8-10. PubMed ID: 11649899
[No Abstract] [Full Text] [Related]
10. A new problem for IRBs: screening for HIV antibodies.
Meyers K
IRB; 1989; 11(6):10-1. PubMed ID: 11650285
[No Abstract] [Full Text] [Related]
11. Reviewing subject recruitment: new rules from Rockville.
McMahon FG
IRB; 1988; 10(3):6-7. PubMed ID: 11651911
[No Abstract] [Full Text] [Related]
12. Ethics review in Canada: highlights from a national workshop, part 2.
Miller JN
Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):29-33. PubMed ID: 11650304
[No Abstract] [Full Text] [Related]
13. Ethical issues in nursing research: access to human subjects.
Scott DW
Top Clin Nurs; 1982 Apr; 4(2):74-83. PubMed ID: 11649725
[No Abstract] [Full Text] [Related]
14. The paradoxical case of payment as benefit to research subjects.
Macklin R
IRB; 1989; 11(6):1-3. PubMed ID: 11650284
[No Abstract] [Full Text] [Related]
15. Protection of human subjects.
United States
Code Fed Regul Shipping; 1982 Oct; Part 46, Sections 46.101 to 46.306():. PubMed ID: 11660819
[No Abstract] [Full Text] [Related]
16. Multicenter trials and subject eligibility: should local IRBs play a role?
Freedman B
IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
[No Abstract] [Full Text] [Related]
17. Protocol review within the context of a research program.
Miller FG; Rosenstein DL
IRB; 1998; 20(4):7-10. PubMed ID: 11657088
[No Abstract] [Full Text] [Related]
18. Ethical aspects of pharmaceutically-based clinical investigation: report on a national workshop.
Miller J; Kinsella D; Klein A; Rusted I
NCBHR Commun; 1990; 1(1):7-10. PubMed ID: 11660185
[No Abstract] [Full Text] [Related]
19. Is post-marketing drug follow-up research or advertising?
Weiss GB; Winslade WJ
IRB; 1987; 9(4):10-1. PubMed ID: 11649947
[No Abstract] [Full Text] [Related]
20. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
Kobasic DM
J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
